Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[1]. - The company's operating revenue for the first half of 2022 was approximately CNY 404.31 million, representing a 30.23% increase compared to CNY 310.46 million in the same period last year[22]. - The net profit attributable to shareholders decreased by 19.81% to approximately CNY 81.66 million, down from CNY 101.84 million in the previous year[22]. - The basic earnings per share for the first half of 2022 was CNY 1.39, a decrease of 21.02% from CNY 1.76 in the same period last year[22]. - The net cash flow from operating activities dropped significantly by 99.61% to approximately CNY 622,765, primarily due to increased cash payments for goods and services[22]. - The company has set a performance guidance of RMB 2.5 billion in revenue for the full year 2022, reflecting a growth target of 20%[1]. - The company's gross profit margin improved to 35%, up from 30% in the same period last year[1]. - The decline in net profit was primarily due to rising prices of raw materials and energy, leading to significantly higher production costs[22]. Research and Development - Research and development expenses increased by 25%, totaling RMB 150 million, focusing on new technology innovations[1]. - Research and development expenses accounted for 4.45% of operating revenue, a decrease of 0.94 percentage points from the previous year[22]. - The company has established a comprehensive innovation system, increasing R&D investment to achieve breakthroughs in core technologies[29]. - The company collaborates with universities and research institutions to enhance its R&D capabilities and accelerate the commercialization of research outcomes[30]. - The company has completed multiple technology reserves, including denitrification molecular sieves and catalysts, and has obtained several national invention patents[48]. - The number of R&D personnel increased from 61 to 78, with R&D personnel accounting for 10.54% of the total workforce[60]. Market Expansion and Strategy - The company plans to launch two new products in Q3 2022, targeting a market expansion of 10% in the next fiscal year[1]. - The company has outlined a strategic goal to enter the Southeast Asian market by the end of 2022, aiming for a market share of 5%[1]. - The company aims to support the "dual carbon" goals through the development of molecular sieve products that facilitate the transition to high-quality development in the petrochemical industry[38]. - The company is actively diversifying its product applications into energy and chemical fields, including coal-to-ethanol and coal-to-propylene[32]. Environmental Compliance and Sustainability - The company emphasizes environmental protection and has invested in new generation environmental treatment systems to reduce production pollution[66]. - The company has implemented a comprehensive wastewater treatment process, including initial sedimentation and pH adjustment, to manage production wastewater[114]. - The company has established a solid waste management system in compliance with national standards to prevent secondary pollution[114]. - The company has installed pollution control facilities, including cyclone separators and low-nitrogen burners, to treat exhaust gases[114]. - The company has reduced electricity consumption and greenhouse gas emissions by optimizing processes in response to national "carbon neutrality" policies[121]. - The company has not reported any significant changes in its environmental compliance status[112]. Risks and Challenges - Risk factors related to supply chain disruptions were highlighted, with potential impacts on production timelines[1]. - The company faces market competition risks from both international and domestic molecular sieve manufacturers, which could weaken its core competitiveness if it fails to innovate[72]. - The company is exposed to risks from rising raw material prices, which could adversely affect its gross margin and profitability if product sales prices do not increase correspondingly[72]. - The company’s overseas market expansion may be negatively impacted by a potential global economic downturn affecting the capacity release and market development of its subsidiary in Thailand[73]. Shareholder Information - The company raised a total of CNY 625.83 million in its initial public offering, with a net amount of CNY 569.92 million after deducting issuance costs[157]. - The total number of shares increased to 59,228,885 after the issuance of 1,235,039 new shares[168]. - The largest shareholder, Li Jianbo, holds 14,350,000 shares, representing 24.23% of total shares[174]. - The top ten shareholders collectively hold a significant portion of the company's equity, with the top three alone accounting for over 39%[174]. - The company has a diverse shareholder base, including both individual and institutional investors[176]. Financial Position - The company's total assets increased by 19.11% to approximately CNY 2.00 billion, up from CNY 1.68 billion at the end of the previous year[22]. - The company's total liabilities reached CNY 588,538,881.07, up from CNY 457,312,255.53, indicating a growth of around 28.7%[190]. - Owner's equity increased to CNY 1,414,493,507.62 from CNY 1,224,339,993.62, showing a growth of about 15.5%[190]. - Cash and cash equivalents amounted to CNY 174,430,726.32, up from CNY 137,604,402.31, representing a growth of approximately 27%[193].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 196,874,549.15, representing a year-on-year increase of 56.95%[5] - The net profit attributable to shareholders was CNY 43,859,750.57, reflecting a growth of 33.59% compared to the same period last year[5] - Basic earnings per share increased by 33.33% to CNY 0.76, driven by the growth in net profit[6] - Total operating revenue for Q1 2022 reached ¥196,874,549.15, a significant increase of 57.0% compared to ¥125,436,139.42 in Q1 2021[21] - Operating profit for Q1 2022 was ¥50,778,720.23, up 47.9% from ¥34,344,529.74 in Q1 2021[22] - Net profit attributable to shareholders for Q1 2022 was ¥43,859,750.57, representing a 33.6% increase from ¥32,831,979.69 in Q1 2021[22] - Basic earnings per share for Q1 2022 was ¥0.76, compared to ¥0.57 in Q1 2021, reflecting a growth of 33.3%[23] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 78.76%, amounting to CNY 10,785,892.97, primarily due to increased cash payments for goods and services[6] - Cash flow from operating activities for Q1 2022 was ¥10,785,892.97, a decrease of 78.8% from ¥50,777,671.14 in Q1 2021[25] - The net cash flow from investing activities was $136,509,698.45, a significant improvement compared to a negative cash flow of $37,391,214.10 in the previous period, indicating a positive shift in investment performance[27] - The total cash and cash equivalents at the end of the period amounted to $434,267,983.98, up from $126,968,233.89 in the previous period, reflecting a net increase of $337,281,493.76[27] - The net cash flow from financing activities was $190,064,928.60, contrasting with a negative cash flow of $20,194,750.00 in the prior period, showcasing a strong financing position[27] - The total cash inflow from financing activities was $193,999,926.12, with cash outflows totaling $3,934,997.52, indicating effective capital management[27] - The company experienced a foreign exchange impact on cash and cash equivalents of -$79,026.26, which is a decrease compared to -$1,857,125.12 in the previous period[27] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 2,041,628,197.18, marking a 21.41% increase from the previous year[6] - As of March 31, 2022, the company's total assets reached RMB 2,041,628,197.18, an increase from RMB 1,681,652,249.15 as of December 31, 2021, reflecting a growth of approximately 21.4%[17] - The total current liabilities increased to RMB 552,415,494.93 from RMB 429,220,526.80, representing an increase of approximately 28.7%[17] - Total liabilities increased to ¥580,031,151.89 in Q1 2022, up from ¥457,312,255.53 in Q1 2021, marking a rise of 26.8%[21] - Total equity attributable to shareholders rose to ¥1,461,597,045.29 in Q1 2022, compared to ¥1,224,339,993.62 in Q1 2021, an increase of 19.4%[21] Research and Development - Research and development expenses totaled CNY 8,284,636.90, accounting for 4.21% of operating revenue, a decrease of 2.15 percentage points[6] - Research and development expenses for Q1 2022 were ¥8,284,636.90, an increase from ¥7,980,224.07 in Q1 2021, indicating a focus on innovation[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,236[11] - The largest shareholder, Li Jianbo, held 14,350,000 shares, representing 24.23% of the total shares[11] Strategic Direction and Market Activity - The company has not disclosed any new product developments or market expansion strategies in the current report[14] - There are no significant changes in the shareholder structure or related party transactions reported for this quarter[13] - The company did not report any new acquisitions or significant market expansions during this quarter, focusing instead on optimizing existing operations[28] - There were no new product launches or technological advancements mentioned in the earnings call, suggesting a period of consolidation[28] - The company has not indicated any changes to its strategic direction or new initiatives for the upcoming quarters[28] Other Financial Metrics - The weighted average return on equity was 3.05%, a decrease of 0.26 percentage points compared to the previous year[6] - Other comprehensive income for Q1 2022 was a loss of ¥260,789.82, compared to a loss of ¥2,225,344.40 in Q1 2021, showing improvement[22] - The company's accounts receivable increased to RMB 55,431,909.15 from RMB 39,781,058.01, reflecting a growth of approximately 39.5%[16] - The total non-current assets amounted to RMB 857,204,599.94, up from RMB 762,422,062.99, indicating an increase of about 12.4%[17] - The company reported a total of RMB 235,000,000.00 in trading financial assets, down from RMB 450,000,000.00, representing a decrease of approximately 47.8%[16] - The company's short-term borrowings and other financial liabilities were not detailed in the provided data, indicating a focus on liquidity management[17] - The cash flow from investment activities decreased from $899,967,957.81 to $676,518,782.68, reflecting a reduction in investment expenditures[27] - The company’s management has confirmed adherence to the new accounting standards effective from 2022, ensuring compliance and transparency in financial reporting[27]

Financial Performance - The company's operating revenue for 2021 was CNY 877,645,727.41, representing a 94.36% increase compared to CNY 451,549,981.64 in 2020[21]. - The net profit attributable to shareholders increased by 116.22% to CNY 275,405,809.23 from CNY 127,370,724.24 in the previous year[23]. - The net profit after deducting non-recurring gains and losses rose by 125.02% to CNY 245,782,797.05, up from CNY 109,229,410.44 in 2020[23]. - The net cash flow from operating activities increased by 204.52% to CNY 387,777,067.99, compared to CNY 127,341,756.34 in the previous year[23]. - The total assets grew by 42.23% to CNY 1,681,652,249.15 from CNY 1,182,374,890.54 in 2020[23]. - The net assets attributable to shareholders increased by 25.62% to CNY 1,224,339,993.62, compared to CNY 974,606,512.80 at the end of 2020[23]. - Basic earnings per share reached CNY 4.76, a 116.36% increase from CNY 2.2 in the previous year[22]. - The weighted average return on equity was 24.16%, an increase of 10.29 percentage points from 13.87% in 2020[22]. Dividend Distribution - The company plans to distribute a cash dividend of 15.00 RMB per 10 shares, totaling approximately 86,990,769.00 RMB, which accounts for 31.59% of the net profit attributable to shareholders for the year 2021[6]. - The cash dividend policy prioritizes cash distribution, with a minimum of 80% cash dividend for mature companies without significant capital expenditure plans[188]. - The company's cash distribution conditions include positive distributable profits and sufficient cash flow, ensuring no impact on ongoing operations[188]. Research and Development - Research and development expenses accounted for 4.80% of operating revenue, up from 4.24% in 2020[22]. - The company reported a significant increase in R&D expenses, with a total of ¥42,145,074.20 in the current year, representing a 120.23% increase compared to ¥19,137,029.89 in the previous year[64]. - The company emphasizes R&D investment and has established a dual-driven R&D model combining independent and collaborative research, enhancing its innovation capabilities[41]. - The company has established joint laboratories with Nankai University and Dalian University of Technology to enhance R&D efforts in carbon capture and molecular sieve technology[62]. - The R&D team is composed of experienced professionals, contributing to the company's innovation and product development[75]. Market Position and Growth - The company attributed its revenue growth to the expanding market for molecular sieves and enhanced production capacity[23]. - The molecular sieve market was valued at $6.4 billion in 2020 and is projected to reach $8.49 billion by 2028, with a compound annual growth rate (CAGR) of 3.8% from 2021 to 2028[54]. - The company is one of the leaders in the domestic molecular sieve industry, with a production scale that ranks among the top globally, continuously expanding its production capacity[44]. - The industrial gas market, where molecular sieves are essential, is expected to grow at a rate approximately 1.4 times that of GDP, indicating increasing demand for molecular sieves[44]. - The company is well-positioned to benefit from the growing demand for molecular sieves in both industrial and medical applications, driven by aging populations and increasing health awareness[50]. Corporate Governance - The board of directors and management have confirmed the accuracy and completeness of the annual report, with no significant omissions or misleading statements[5]. - The company has established a complete governance structure, ensuring independent operation of the board of directors, supervisory board, and management team, promoting healthy and sustainable development[156]. - The company has implemented strict information disclosure practices, ensuring transparency and equal access to information for all shareholders[157]. - The company has not faced any issues regarding independence or operational autonomy from its controlling shareholders[158]. - The company has established a compensation and assessment committee under the board of directors to oversee the remuneration and evaluation of senior executives[200]. Risks and Challenges - The company has outlined potential risk factors in its operations, which are detailed in the management discussion and analysis section[5]. - The company faces risks related to product iteration, as competitors may introduce more efficient molecular sieves, potentially impacting market share[80]. - The company is exposed to raw material price fluctuations, which could adversely impact performance if sales prices do not adjust accordingly[83]. - The ongoing COVID-19 pandemic may affect the capacity release and market expansion of the company's overseas projects[87]. - The company is subject to macroeconomic risks that could impact its operations and financial performance[86]. Production and Capacity - The company has a total production capacity of 45,000 tons for molded molecular sieves and activated molecular sieves, positioning it favorably in the domestic market compared to peers[54]. - The company added 10,000 tons of molecular sieve raw powder capacity and 22,000 tons of molded molecular sieve capacity during the reporting period[134]. - The average capacity utilization rates for molecular sieve raw powder, activated powder, molded molecular sieve, and activated alumina were 106.45%, 79.37%, 89.10%, and 63.32% respectively[135]. - The company has developed molecular sieve products with a production capacity of 41,000 tons for raw powder and 42,000 tons for shaped molecular sieves as of December 31, 2021[74]. Employee and Management - The total number of employees in the parent company is 659, and in major subsidiaries, it is 63, resulting in a total of 722 employees[184]. - The company has established a salary policy that emphasizes performance-based distribution and aims to enhance employee motivation and innovation[185]. - The company has a training plan that includes targeted skills training for employees based on their positions and levels, as well as management training to improve leadership capabilities[186]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 6.6922 million RMB[171]. - The company has implemented a performance assessment mechanism for senior management to ensure accountability[200].

Financial Performance - The company's revenue for Q3 2021 reached ¥296,130,931.33, representing a year-on-year increase of 115.35%[5] - Net profit attributable to shareholders for the same period was ¥98,776,619.60, up 129.72% compared to the previous year[5] - The basic earnings per share for Q3 2021 was ¥1.71, reflecting an increase of 131.08% year-on-year[6] - Total operating revenue for the first three quarters of 2021 reached ¥606,591,150.96, a significant increase from ¥319,540,960.44 in the same period of 2020, representing an increase of approximately 89.9%[19] - Net profit for the first three quarters of 2021 was ¥200,619,524.75, up from ¥93,779,491.23 in 2020, indicating a growth of approximately 113.4%[21] - The total comprehensive income for the third quarter of 2021 was CNY 190,621,471.44, compared to CNY 93,779,491.23 in the same period of 2020, representing an increase of 103.5%[22] - Basic and diluted earnings per share for Q3 2021 were CNY 3.47, up from CNY 1.62 in Q3 2020, reflecting a growth of 114.2%[22] Assets and Liabilities - Total assets as of the end of the reporting period amounted to ¥1,576,907,500.35, a growth of 33.37% from the previous year[6] - The total assets as of the end of the third quarter of 2021 amounted to ¥1,576,907,500.35, compared to ¥1,182,374,890.54 at the end of the previous year, marking an increase of about 33.4%[17] - Total liabilities as of the end of the third quarter of 2021 were ¥437,534,048.14, up from ¥207,768,377.74 in the previous year, which is an increase of approximately 110.9%[17] - The company's fixed assets were valued at ¥514,884,937.70, compared to ¥351,455,661.48 in the previous year, reflecting an increase of about 46.5%[17] - Total liabilities amounted to 207,768,377.74, with current liabilities at 192,200,265.44[28] - Non-current liabilities totaled 15,568,112.30, including deferred income of 11,669,186.06 and deferred tax liabilities of 3,898,926.24[28] Cash Flow - The net cash flow from operating activities was ¥336,714,681.17, an increase of 265.54% compared to the same period last year[6] - Cash inflow from operating activities for the first three quarters of 2021 was CNY 554,609,430.46, significantly higher than CNY 239,304,252.47 in the same period of 2020, marking an increase of 131.7%[24] - The net cash flow from operating activities for the first three quarters of 2021 was CNY 336,714,681.17, compared to CNY 92,113,454.12 in 2020, indicating a growth of 264.5%[24] - The net cash flow from investment activities for the first three quarters of 2021 was -CNY 185,925,680.02, a decrease from CNY 113,788,066.39 in 2020[24] - The net cash flow from financing activities for the first three quarters of 2021 was -CNY 70,730,847.22, compared to -CNY 91,925,769.50 in 2020, showing an improvement of 23.0%[25] Research and Development - Research and development expenses totaled ¥11,267,299.30, which is 3.80% of revenue, marking an increase of 0.41 percentage points year-on-year[6] - Research and development expenses for the first three quarters of 2021 totaled ¥28,002,405.20, compared to ¥11,464,272.78 in 2020, indicating an increase of approximately 144.4%[19] Equity - The total equity attributable to shareholders was ¥1,139,373,452.21, reflecting a year-on-year increase of 16.91%[6] - The total equity attributable to shareholders of the parent company was ¥1,139,373,452.21, up from ¥974,606,512.80 in the previous year, indicating an increase of approximately 16.9%[17] Operational Insights - The company attributed revenue growth to the gradual release of new production capacity and optimization of product structure[9] - The company completed the construction and commissioning of new production lines in the first half of 2021, contributing to increased capacity and revenue[9] - The company reported a significant increase in sales revenue, with cash received from sales of goods and services amounting to CNY 516,069,512.01 for the first three quarters of 2021, compared to CNY 225,407,141.34 in 2020, an increase of 129.0%[23] Future Outlook - The company has not disclosed any significant new product developments or market expansion strategies during the reporting period[14] - There were no significant mergers or acquisitions reported in the third quarter of 2021[14] - The company did not provide specific future guidance or outlook for the upcoming quarters[14] - The company has implemented new leasing standards starting from 2021, which may impact financial reporting and asset management strategies moving forward[26]

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2021, representing a year-on-year increase of 20%[14]. - The company's operating revenue for the first half of the year reached approximately CNY 310.46 million, representing a 70.56% increase compared to the same period last year[22]. - The net profit attributable to shareholders increased by 100.56% year-on-year, amounting to approximately CNY 101.84 million[22]. - Basic earnings per share rose to CNY 1.76, a 100% increase from the previous year[23]. - The net cash flow from operating activities surged by 280.01%, reaching approximately CNY 158.99 million[22]. - The company's oxygen business generated sales revenue of CNY 178.84 million, with healthcare oxygen molecular sieve sales accounting for approximately 37.28% of total revenue[87]. - The sales revenue of hydrogen molecular sieves reached CNY 22.77 million in the first half of 2021, representing a year-on-year growth of 86.38%[87]. Research and Development - The company is investing RMB 50 million in R&D for new technologies related to molecular sieves and gas separation[14]. - The company's R&D investment as a percentage of operating revenue increased to 5.39%, up from 3.74% in the previous year, marking a 1.65 percentage point increase[21]. - The company has achieved a significant increase in R&D investment, with total R&D expenses amounting to ¥16,735,105.90, a 146.07% increase compared to the previous period[68]. - The average salary of R&D personnel increased significantly to ¥150,758.66, compared to ¥45,808.97 in the previous period, indicating a focus on talent retention and motivation[77]. - The company holds a total of 20 authorized invention patents and 50 utility model patents as of the report date, with a total of 94 intellectual property rights[66]. Market Expansion and Strategy - Future outlook includes a projected revenue growth of 25% for the full year 2021, driven by market expansion and new product launches[14]. - Market expansion efforts include entering Southeast Asian markets, with an expected revenue contribution of RMB 30 million in 2022[14]. - The company is actively expanding its capacity in Southeast Asia to support its international development strategy, with projects expected to be completed by the end of 2021[89]. - The company aims to improve its market position and product structure to compete with international giants like Honeywell UOP and Arkema[63]. Product Development and Innovation - The company plans to launch two new products in Q3 2021, which are expected to contribute an additional RMB 100 million in revenue[14]. - The company is advancing projects in environmental governance and energy chemical fields, focusing on the development of catalysts and adsorbents for various applications[90]. - The company has developed core technologies for producing molecular sieves from raw powder to formed products, enhancing brand recognition and market share against competitors[42]. - The company is focusing on high-value-added products, particularly in the oxygen production sector, with successful applications in large-scale VPSA oxygen production projects[86]. Financial Position and Assets - The total assets of the company at the end of the reporting period were approximately CNY 1.33 billion, a 12.14% increase from the end of the previous year[22]. - The net assets attributable to shareholders increased by 6.75% to approximately CNY 1.04 billion[22]. - The company's total current assets amounted to ¥710,675,461.70, a slight decrease from ¥717,715,430.63 at the end of 2020, representing a decrease of approximately 1.5%[196]. - The cash and cash equivalents were reported at ¥258,980,163.03, an increase from ¥142,665,624.88 in December 2020, indicating a growth of approximately 81.5%[196]. - The total fixed assets reached ¥415,659,704.14, up from ¥351,455,661.48, marking an increase of approximately 18.3%[196]. Environmental and Social Responsibility - The company has implemented advanced environmental protection facilities, reducing production costs and pollutant emissions through recycling processes[83]. - The company has achieved a green coverage area of 31,358.9 m², representing a green coverage rate of 37.38% of the outdoor area[126]. - The company has actively participated in social welfare, providing 33,400 yuan in aid to the elderly and donating 4,000 yuan to impoverished families[128]. - The company invested 504,000 yuan in the repair of community roads to enhance local infrastructure[129]. Shareholder Commitments and Governance - The company reported a commitment from major shareholders, including the actual controller, to not transfer or delegate management of shares held prior to the IPO for 36 months[134]. - Shareholders are restricted from transferring more than 25% of their shares annually while serving as directors or senior management, and for six months post-departure[136]. - The company has established a commitment to not repurchase shares held prior to the IPO during the specified lock-up periods[138]. - Major shareholders, including the actual controller, have made commitments regarding share transfers and management during their tenure[139]. Risks and Challenges - The company faces risks related to product iteration, technology commercialization, and potential loss of core technical personnel, which could impact its competitive position[93]. - The domestic molecular sieve industry faces challenges in technology maturity and market application compared to developed countries, but opportunities for growth are increasing[33].

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2021, representing a year-on-year increase of 15%[14]. - The net profit attributable to shareholders reached RMB 300 million, up 20% compared to the same period last year[14]. - The company's operating revenue for the first half of the year reached approximately CNY 310.46 million, representing a 70.56% increase compared to the same period last year[22]. - The net profit attributable to shareholders increased by 100.56% year-on-year, amounting to approximately CNY 101.84 million[22]. - Basic earnings per share rose to CNY 1.76, a 100% increase from CNY 0.88 in the previous year[23]. - The net cash flow from operating activities surged by 280.01%, reaching approximately CNY 158.99 million, driven by increased sales revenue[22]. - Future guidance estimates a revenue growth of 10-15% for the second half of 2021, driven by increased demand in the industrial sector[14]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2022[14]. - The company has no plans for mergers or acquisitions in the near term, focusing instead on organic growth strategies[14]. - The company is actively expanding its capacity layout in Southeast Asia to support its international development strategy[87]. - The company aims to expand its market share by enhancing its brand and leveraging its manufacturing advantages to compete with international molecular sieve enterprises[81]. Research and Development - The company has allocated RMB 100 million for research and development in advanced materials technology for the upcoming fiscal year[14]. - The company's R&D investment as a percentage of operating revenue increased to 5.39%, up from 3.74% in the previous year, reflecting a 1.65 percentage point increase[21]. - The company has achieved a significant increase in R&D investment, with total R&D expenses amounting to ¥16,735,105.90, a 146.07% increase compared to the previous period[67]. - The company is focusing on new product development, including a new type of molecular sieve for hydrogen purification and specialized activated powders for polyurethane adhesives[71]. - The company has established a comprehensive innovation system and increased R&D investment to achieve breakthroughs in core technologies through independent and collaborative research[32]. Product Development and Technology - New product development includes the launch of a high-efficiency molecular sieve, expected to increase production capacity by 40%[14]. - The company has developed core technologies for producing molecular sieves from raw powder to formed products, enhancing brand recognition and market share against competitors[42]. - The company is focusing on high-value-added products, particularly in the oxygen production sector, with successful applications in large-scale VPSA oxygen production projects[84]. - The company is advancing the development of molecular sieves for environmental governance, including products for flue gas denitrification and nuclear wastewater treatment[51]. Environmental and Social Responsibility - The company has established a wastewater treatment station to manage production wastewater, employing various treatment processes to ensure compliance with environmental standards[117]. - The company has implemented pollution control facilities, including cyclone separators and low-nitrogen burners, to treat emissions before discharge[116]. - The company has actively participated in social welfare, providing 33,400 yuan in aid to the elderly and donating 4,000 yuan to impoverished families[125]. - The company has committed to fulfilling various promises related to share restrictions and compliance with regulations[130]. Risks and Challenges - The management highlighted potential risks including supply chain disruptions and fluctuating raw material prices, which could impact future performance[14]. - The company is facing risks related to product iteration, technology commercialization, and potential loss of core technical personnel, which could impact its competitive position[91]. - The domestic molecular sieve industry faces challenges in technology maturity and market application compared to developed countries, but there are opportunities for growth due to increasing domestic demand[33]. Shareholder and Corporate Governance - The company guarantees that its IPO prospectus and related documents do not contain false statements or omissions, taking legal responsibility for their accuracy and completeness[24]. - The company has established a lock-up period of at least 6 months if the stock price falls below the IPO price for 20 consecutive trading days[134]. - Shareholders are restricted from transferring more than 25% of their shares annually during their tenure as directors or senior management[133]. - The company must announce specific reduction situations within 2 trading days after the completion of the share reduction plan[144].

Financial Performance - The company's operating revenue for 2020 was approximately CNY 451.55 million, representing an increase of 11.23% compared to 2019[24]. - Net profit attributable to shareholders increased by 48.10% to CNY 127.37 million, while the net profit after deducting non-recurring gains and losses rose by 59.71% to CNY 109.23 million[24][26]. - Basic earnings per share rose to CNY 2.20, a 13.99% increase year-on-year, reflecting the growth in net profit[27]. - The company's total assets at the end of 2020 were CNY 1.18 billion, a 2.19% increase from 2019[24]. - The company's net cash flow from operating activities surged by 206.08% to CNY 127.34 million, driven by increased sales and reduced cash payments for goods[27]. - The company reported a total revenue of 18,910,000.00 RMB for the year, with a net profit of 16,970,962.18 RMB, indicating a slight increase in profitability compared to the previous year[81]. - The company's operating profit for the same period was 147.13 million yuan, showing a significant increase of 73.39% year-on-year[96]. - The company achieved a gross margin of 44.39% in the chemical raw materials and chemical manufacturing sector, an increase of 5.5 percentage points compared to the previous year[126]. Dividend Policy - The company plans to distribute a cash dividend of RMB 7 per 10 shares, totaling RMB 40,474,000, which accounts for 31.78% of the net profit attributable to shareholders for 2020[7]. - The cash dividend distribution is based on the share capital as of the dividend record date, with a proposed distribution of RMB 0.7 per 10 shares[185]. - The company has established a profit distribution policy prioritizing cash dividends, with a minimum of 80% for mature stages without major capital expenditures[181]. - The company's cash flow is deemed sufficient to support the proposed cash dividend without affecting its ongoing operations[181]. - The board of directors has approved the profit distribution plan, pending shareholder meeting approval for implementation[182]. Research and Development - Research and development expenses accounted for 4.24% of operating revenue, an increase of 0.66 percentage points compared to the previous year[25]. - The total R&D investment for the year was approximately ¥19.14 million, an increase of 31.68% compared to the previous year, representing 4.24% of total revenue[75][76]. - The company obtained 26 new intellectual property rights during the reporting period, including 8 invention patents and 17 utility model patents[73][74]. - The company has established collaborations with research institutions to enhance innovation and product development[73]. - The company is focusing on the development of molecular sieve catalysts for environmental governance, including products for coal-to-ethanol and diesel vehicle exhaust denitration[44]. Market Expansion and Strategy - The company aims to further optimize its sales structure and expand its market presence in the healthcare sector, particularly in oxygen production materials[26]. - The company is expanding its production capacity through projects like the "Adsorption Material Industrial Park Expansion Project" and the "Thailand Subsidiary Construction Project" to strengthen its market position[53]. - The company aims to expand its business into hydrogen purification, coal-based ethanol, and environmental remediation sectors, enhancing its product structure and market reach[178]. - The company is actively expanding its market presence in the environmental governance and energy chemical sectors, focusing on high-value-added product upgrades[98]. - The company has established a comprehensive innovation system and increased R&D investment to achieve breakthroughs in core technologies through independent research and development[42]. Operational Risks and Governance - The company has detailed various operational risks and corresponding mitigation measures in the report[5]. - The report includes a standard unqualified audit opinion from Lixin Certified Public Accountants[6]. - The company has no non-operating fund occupation by controlling shareholders or related parties[9]. - There are no violations of decision-making procedures for external guarantees[10]. - The company has not disclosed any special arrangements for corporate governance[10]. Production and Capacity - The company's total production capacity is 93,000 tons per year, with a global market share of 4.43% in production and 4.24% in output for formed molecular sieves and activated molecular sieve powders in 2018, ranking sixth globally[53]. - The company has a production capacity of 31,000 tons of molecular sieve raw powder, 20,000 tons of formed molecular sieves, and 3,000 tons of activated molecular sieves, with an additional 10,000 tons of formed molecular sieve production line in trial production[53]. - The company completed the construction of a 4,500-ton oxygen-rich molecular sieve production line in the second quarter, and a 9,000-ton hydrogen and oxygen molecular sieve production line is in trial production[101]. - The company is focusing on expanding production capacity to meet increasing demand for molecular sieve products[129]. Customer Base and Sales - The company has established a stable customer base, including major domestic enterprises like Sinopec and international giants like Praxair[90]. - The company achieved sales revenue of 374.05 million yuan from molded molecular sieves, accounting for 82.84% of total revenue during the reporting period[101]. - The sales revenue from the oxygen production series reached 255.99 million yuan, representing 56.69% of total revenue, with a year-on-year growth of 39.26%[103]. - The sales of molded molecular sieves increased by 17.32%, contributing to a gross margin increase of 7.12 percentage points[128]. - The sales of molecular sieve raw powder decreased by 22.65%, resulting in a gross margin reduction of 6.94 percentage points[126]. Financial Management - The company faced risks related to raw material price increases, which could adversely affect performance if product prices do not adjust accordingly[118]. - The company is exposed to foreign exchange risks due to a significant portion of its business being export-oriented[118]. - The company's financial expenses decreased by 60.56%, reflecting improved cost management[123]. - The company benefited from an increase in the export tax rebate rate from 6% to 13% for its molecular sieve products, which positively impacted profitability[119]. - The company has maintained stable energy procurement costs, with natural gas prices down by 7.68% and electricity costs down by 3.86% year-on-year[168].

证券代码：688357 证券简称：建龙微纳 公告编号：2021-034 洛阳建龙微纳新材料股份有限公司 关于参加河南辖区上市公司 2021 年投资者网上集体 接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步加强与投资者的互动交流，洛阳建龙微纳新材料股份有限公司（以 下简称"公司"）定于 2021 年 6 月 8 日（周二）16:00-17:20 在线参加在全景网 举办的"真诚沟通 传递价值"河南辖区上市公司 2021 年投资者网上集体接待 日活动。本次活动将采用网络远程的方式举行，投资者可登录"全景·路演天下" （http://rs.p5w.net）参与本次互动交流。 出席本次网上集体接待日活动的人员有：公司副总裁兼董事会秘书李怡丹女 士及相关工作人员（如有特殊情况，参会人员将可能进行调整）。本次活动中， 将主要就 2020 年度经营情况、公司发展战略等投资者所主要关心的问题进行沟 通交流。 欢迎广大投资者积极参与。 特此公告。 洛阳建龙微纳新材料股份有限公司董事会 2021 年 6 月 3 日 ...

Financial Performance - Net profit attributable to shareholders rose by 123.42% to CNY 32,831,979.69 year-on-year[6] - Operating revenue increased by 65.83% to CNY 125,436,139.42 compared to the same period last year[6] - Basic earnings per share increased by 128.00% to CNY 0.57 compared to CNY 0.25 in the same period last year[6] - The company reported a net profit of ¥237,987,708.04 for the first quarter of 2021, compared to ¥204,847,847.06 in the same period of 2020, marking an increase of approximately 16.1%[25] - Operating profit for Q1 2021 was ¥34,344,529.74, up 92.0% from ¥17,878,849.24 in Q1 2020[28] - The company reported a total profit of ¥37,728,129.74 for Q1 2021, up 121.5% from ¥17,027,535.03 in Q1 2020[28] - Comprehensive income for Q1 2021 totaled ¥30,606,635.29, significantly higher than ¥14,695,298.36 in Q1 2020[29] Cash Flow - The net cash flow from operating activities was CNY 50,777,671.14, a significant improvement from a negative CNY 2,703,474.01 in the previous year[6] - The company's cash flow from operating activities improved significantly, reaching RMB 50,777,671.14, compared to a negative cash flow of RMB -2,703,474.01 in the previous year[15] - In Q1 2021, the cash inflow from sales of goods and services reached ¥94,203,119.65, a significant increase of 111.7% compared to ¥44,621,914.19 in Q1 2020[35] - The total cash outflow for operating activities was ¥54,945,227.11, which is an increase from ¥48,118,375.09 in the previous year[36] - The ending balance of cash and cash equivalents was ¥126,968,233.89, compared to ¥85,590,041.55 at the end of Q1 2020, reflecting a year-over-year increase of 48.2%[36] Assets and Liabilities - Total assets increased by 2.58% to CNY 1,212,918,875.44 compared to the end of the previous year[6] - Contract assets decreased by 32.42% to RMB 5,020,910.77, primarily due to the expiration of certain warranty deposits[14] - Other current assets increased by 144.57% to RMB 633,172.18, mainly due to an increase in deductible input tax[14] - The company reduced its short-term borrowings by 66.67%, from RMB 30,000,000.00 to RMB 10,000,000.00, reflecting repayment of bank loans during the reporting period[14] - Current liabilities decreased to ¥189,897,969.73 from ¥195,312,750.19, a reduction of about 2.1%[24] - Non-current liabilities totaled ¥15,343,329.35, slightly down from ¥15,568,112.30, indicating a decrease of approximately 1.5%[20] - The total liabilities decreased to ¥205,241,299.08 from ¥210,880,862.49, a decline of about 2.5%[24] Research and Development - R&D investment accounted for 6.36% of operating revenue, up by 2.88 percentage points from the previous year[6] - Research and development expenses surged by 203.26% to RMB 7,980,224.07, driven by increased investment in ongoing projects and higher share-based payment costs for R&D personnel[15] - Research and development expenses increased to ¥7,980,224.07 in Q1 2021, up 203.0% from ¥2,631,445.93 in Q1 2020[27] Shareholder Information - The total number of shareholders reached 4,087 at the end of the reporting period[10] - The top shareholder, Li Jianbo, holds 24.82% of the shares, totaling 14,350,000 shares[10] Other Income and Expenses - Non-recurring gains and losses amounted to CNY 4,799,689.77, including CNY 5,000,000 from government subsidies[8][9] - Other income for Q1 2021 was ¥5,100,000.00, compared to ¥495,000.00 in Q1 2020, indicating a substantial increase[28] - The company experienced a credit impairment loss of ¥62,003.40 in Q1 2021, compared to a gain of ¥5,744.43 in Q1 2020[27]

Financial Performance - The company's operating revenue for 2020 was CNY 451,549,981.64, representing an increase of 11.23% compared to 2019[24]. - Net profit attributable to shareholders increased by 48.10% to CNY 127,370,724.24, while the net profit after deducting non-recurring gains and losses rose by 59.71% to CNY 109,229,410.44[24][26]. - The gross profit margin improved to 44.39%, up by 5.50 percentage points from the previous year[26]. - The net cash flow from operating activities surged by 206.08% to CNY 127,341,756.34, driven by increased sales and optimized sales structure[27]. - Basic earnings per share increased by 13.99% to CNY 2.20, reflecting the growth in net profit[27]. - The company achieved a total revenue of 451.55 million yuan in 2020, representing a year-on-year growth of 11.23%[98]. - The operating profit for the same period was 147.13 million yuan, showing a significant increase of 73.39% year-on-year[98]. - The company reported a total revenue of 18,910,000.00 RMB for the year, with a slight increase from 16,970,962.18 RMB in the previous year, representing a growth of approximately 5.5%[82]. Dividend Policy - The company plans to distribute a cash dividend of RMB 7 per 10 shares, totaling RMB 40,474,000, which accounts for 31.78% of the net profit attributable to shareholders for 2020[7]. - The cash dividend distribution policy prioritizes cash dividends, with a minimum of 80% for mature companies without significant capital expenditures[181]. - The company’s 2020 cash dividend proposal has been approved by the board and is pending shareholder approval[182]. - The company’s cash dividend policy is designed to protect the rights of minority investors[182]. - The company has established a profit distribution system to enhance transparency and operational feasibility[181]. Research and Development - Research and development expenses accounted for 4.24% of operating revenue, an increase of 0.66 percentage points from 2019[25]. - The total R&D investment for the year was approximately ¥19.14 million, an increase of 31.68% compared to the previous year[75]. - The total R&D expenditure accounted for 4.24% of the company's operating revenue, up from 3.58% in the previous year, indicating a growth of 18.44%[76]. - The company obtained 26 new intellectual property rights during the reporting period, including 8 invention patents and 17 utility model patents[73]. - The company has established several research and innovation platforms, including the "Henan Province Adsorption Molecular Sieve Engineering Technology Research Center" to drive product development[151]. Market and Industry Trends - The global zeolite market is expected to grow at a compound annual growth rate (CAGR) of 5.65% from 2020 to 2025, reaching a market size of $4.39 billion by 2025[46]. - The domestic zeolite industry is experiencing increased demand due to stricter environmental regulations and the push for carbon neutrality, with significant opportunities in VOCs treatment and nitrogen oxides pollution prevention[47][49]. - The market size for VOCs治理 in China was approximately 74.1 billion yuan in 2020, projected to exceed 130 billion yuan by 2025, reflecting a CAGR of 13%[50]. - The hydrogen energy sector is anticipated to create a market value of $2.5 trillion by 2050, with hydrogen production accounting for over 90% of hydrogen consumption in industrial applications[58]. Operational Risks and Compliance - The company has detailed various operational risks and corresponding mitigation measures in the report[5]. - The report includes a standard unqualified audit opinion from Lixin Certified Public Accountants[6]. - The company has no non-operating fund occupation by controlling shareholders or related parties[9]. - There are no violations of decision-making procedures for external guarantees[10]. - The company’s future plans and development strategies are subject to investment risks and do not constitute a commitment to investors[8]. Production and Capacity - The company has established a wholly-owned subsidiary in Thailand, expanding its international presence[13]. - The company's total production capacity is 93,000 tons/year, with a global market share of 4.43% in production capacity and 4.24% in output for molded molecular sieves and activated molecular sieve powders, ranking sixth globally[53]. - The company has a total capacity of 31,000 tons for molecular sieve raw powder, 20,000 tons for molded molecular sieves, and 3,000 tons for activated molecular sieves, with ongoing projects to expand production capacity[53]. - The company completed the construction of a 4,500-ton oxygen-rich molecular sieve production line in the second quarter, and a 9,000-ton efficient hydrogen and oxygen molecular sieve production line is in trial production[102]. Customer and Supplier Relations - The company has established a stable customer base, including major domestic enterprises like Sinopec and international giants like Praxair[91]. - The top five customers contributed 10,704.50 million RMB, accounting for 21.40% of the total annual sales[135]. - The top five suppliers accounted for 30.35% of the total annual purchases, with a total procurement amount of 9,952.78 million RMB[139]. Environmental and Sustainability Initiatives - The company emphasizes continuous innovation and has established a robust R&D capability to maintain competitiveness against international peers[35]. - The company’s strategic focus includes enhancing energy efficiency and environmental remediation, aligning with national policies on sustainable development[36]. - The company has implemented advanced environmental protection facilities, including a 4,000 t/d wastewater treatment plant and a 450 t/d MVR desalination facility[94]. Financial Position and Assets - The company’s cash and cash equivalents at the end of the period were 142,665,624.88 RMB, representing 12.07% of total assets[144]. - The total assets increased by 13.02% compared to the previous year, with fixed assets amounting to 351,455,661.48 RMB[144]. - The company reported a significant increase in deferred income tax assets, rising to CNY 2,549,053.73, up 49.64% from CNY 1,703,482.19[146]. Shareholder Commitments and Regulations - The company reported a commitment to not transfer or manage shares held prior to the IPO for 36 months from the date of listing[188]. - Shareholders are restricted from transferring more than 25% of their shares annually while serving as directors or senior management[189]. - The company has established a policy to ensure compliance with relevant laws and regulations regarding share transfers by directors and senior management[192].